David Raben
Board Member
Bicara Therapeutics Inc. (BCAX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David Raben
David Raben is recorded as Board Member at Bicara Therapeutics Inc. (BCAX). The proxy statement of Bicara Therapeutics Inc. reports total compensation of $709,164 for David Raben in fiscal 2025, including a base salary of $525,000.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Bicara Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- Claire Mazumdar CEO
- Carolyn Ng Board Member
- Christopher Bowden Board Member
- Christy Oliger Board Member
- Ivan Hyep Board Member
- Jeremy Bender, Ph.D. Board Member
- Lara Meisner Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bicara Therapeutics Inc. (BCAX) | Chief Medical Officer The amounts reported represent the aggregate grant date fair value of stock option awards granted to our named executive officers during the applicable fiscal years, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. A discussion of the assumptions used in determining grant date fair value may be found in Note 10 to our financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon exercise of the applicable award or sale of the underlying shares of stock. The amounts reported for the fiscal year ended December 31, 2025 represent the annual bonuses each named executive officer earned under our annual cash bonus program based on achievement of company performance and individual performance during the applicable fiscal year, which were paid in the first quarter of fiscal year following the applicable fiscal year. The amounts reported represent employer profit sharing contributions and employer matching contributions earned by our named executive officers under our 401(k) plan during the applicable fiscal years. Dr. Raben was not a named executive officer for the fiscal year ended December 31, 2024. | $525,000 | $709,164 |
Recent activity
No call appearances or filed executive changes recorded yet.